AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9057731 — intervention group
Group type: COMPARATOR
Intervention: Circumcision with placebo
Number of subjects: 87
Study 9057731 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision with Emla
Number of subjects: 87
Study 8198628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg/2 wk
Number of subjects: 283
Study 8198628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylestriol 1 mg/2 wk
Number of subjects: 283
Study 8198628 — intervention group
Group type: COMPARATOR
Intervention: Placebo/2 wk
Number of subjects: 283
Study 3085844 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position with bumetanide 1 mg intravenously
Number of subjects: 12
Study 3085844 — intervention group
Group type: COMPARATOR
Intervention: Upright position with bumetanide 1 mg intravenously
Number of subjects: 12
Study 31906925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet
Number of subjects: 254
Study 31906925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral information session
Number of subjects: 254
Study 31906925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet and oral information session
Number of subjects: 254
Study 31906925 — intervention group
Group type: COMPARATOR
Intervention: No information
Number of subjects: 254
Study 30054245 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Benzoyl peroxide (BPO)
Number of subjects: 80
Study 30054245 — intervention group
Group type: COMPARATOR
Intervention: 4% Chlorhexidine gluconate (CHG)
Number of subjects: 80
Study 30054245 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Benzoyl peroxide (BPO) and 4% Chlorhexidine gluconate (CHG)
Number of subjects: 80
Study 26962308 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Midazolam/Remifentanil (PMR)
Number of subjects: 32
Study 26962308 — intervention group
Group type: COMPARATOR
Intervention: Propofol/Midazolam/Ketamine (PMK)
Number of subjects: 32
Study 24905063 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and progestin therapy
Number of subjects: 215
Study 24905063 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol, progestin, and testosterone therapy
Number of subjects: 215
Study 24905063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 215
Study 24905063 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 215
Study 22395196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide group (received conventional treatment plus nesiritide infusion at 0.0075-0.015 μg·kg(‐1)·min(‐1) for 10-15 hours, total 0.5-1.0 mg once daily for 13 days)
Number of subjects: 140
Study 22395196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide group
Number of subjects: 140
Study 22395196 — intervention group
Group type: COMPARATOR
Intervention: Control group (received only conventional treatment for AHF)
Number of subjects: 140
Study 20089489 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 0.7 to 1.4 mg/kg per day
Number of subjects: 306
Study 20089489 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 0.1 to 0.2 mg/kg per day up to 5 mg/d
Number of subjects: 306
Study 20089489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 18928837 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional inferior alveolar technique
Number of subjects: 40
Study 18928837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates technique
Number of subjects: 40
Study 18928837 — intervention group
Group type: EXPERIMENTAL
Intervention: Vazirani-Akinosi technique
Number of subjects: 40
Study 16106336 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized motivational intervention (IMI) provided by nurses with telephone reminders 1 week after the intervention
Number of subjects: 80
Study 16106336 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 12587767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated sugar (10 ppm fluoride)
Number of subjects: 176
Study 12587767 — intervention group
Group type: COMPARATOR
Intervention: Normal sugar
Number of subjects: 176
Study 10363572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (1.8 or 3.6 g/day)
Number of subjects: 11
Study 7727768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination (ZDV 150 mg and ddl 134 mg, daily)
Number of subjects: 126
Study 7727768 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose combination (ZDV 300 mg and ddl 334 mg, daily)
Number of subjects: 126
Study 7727768 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose combination (ZDV 600 mg and ddl 500 mg, daily)
Number of subjects: 126
Study 7727768 — intervention group
Group type: EXPERIMENTAL
Intervention: ddl monotherapy (ddl 500 mg, daily)
Number of subjects: 126
Study 7727768 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms combined
Number of subjects: 126
Study 2201495 — intervention group
Group type: EXPERIMENTAL
Intervention: Max EPA fish oil supplement (15 capsules/day with meals)
Number of subjects: 22
Study 2201495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Max EPA)
Number of subjects: 22
Study 6160020 — intervention group
Group type: EXPERIMENTAL
Intervention: Kwell Shampoo (gamma benzene hexachloride; lindane)
Number of subjects: 15
Study 6160020 — intervention group
Group type: COMPARATOR
Intervention: RID (pyrethrin-based pediculicide)
Number of subjects: 15
Study 31319786 — intervention group
Group type: EXPERIMENTAL
Intervention: BC+R (provider advice and cessation assistance + three sessions of in-person counseling)
Number of subjects: 89
Study 31319786 — intervention group
Group type: COMPARATOR
Intervention: BC (provider advice and cessation assistance)
Number of subjects: 89
Study 31319786 — intervention group
Group type: EXPERIMENTAL
Intervention: BC+R
Number of subjects: 89
Study 31564142 — intervention group
Group type: EXPERIMENTAL
Intervention: Single thick Kirschner wire (K-wire)
Number of subjects: 290
Study 31564142 — intervention group
Group type: COMPARATOR
Intervention: Dual thin Kirschner wires
Number of subjects: 290
Study 27740719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 467
Study 27740719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study 25869369 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive stimulation
Number of subjects: 1489
Study 25869369 — intervention group
Group type: COMPARATOR
Intervention: Enhanced nutrition
Number of subjects: 1489
Study 25869369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 1489
Study 25869369 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 1489
Study 23528655 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (2 × 15 J/cm²‐clean‐2 × 15 J/cm²)
Number of subjects: 41
Study 23528655 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified regimen (3 × 15 J/cm²‐no clean)
Number of subjects: 41
Study 21307846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 600 mg
Number of subjects: 24
Study 21307846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21307846 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 24
Study 19593240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vision rehabilitation
Number of subjects: 24
Study 19593240 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 24
Study 17188087 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% talactoferrin gel
Number of subjects: 55
Study 17188087 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.5% talactoferrin gel
Number of subjects: 55
Study 17188087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15536575 — intervention group
Group type: EXPERIMENTAL
Intervention: Study solution (2 mg of morphine, 15 mg of bupivacaine, 80 mg of methylprednisolone, and 0.05 mg of adrenaline)
Number of subjects: 40
Study 15536575 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 40
Study 10767223 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast alone, 10 mg (ML(10))
Number of subjects: 12
Study 10767223 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol alone, 50 microg (SM(50))
Number of subjects: 12
Study 10767223 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) and salmeterol (50 microg)
Number of subjects: 12
Study 10767223 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg) and inhaled salmeterol, 100 microg (SM(100))
Number of subjects: 12
Study 10767223 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler and tablet
Number of subjects: 12
Study 10767223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies vs ML(10) alone
Number of subjects: 12
Study 9067044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms iv
Number of subjects: 60
Study 9067044 — intervention group
Group type: COMPARATOR
Intervention: Saline bolus iv
Number of subjects: 60
Study 8354335 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 23
Study 8354335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 23
Study 8354335 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Pravastatin
Number of subjects: 23
Study 2942886 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNG (30 mg applied 30 minutes before induction)
Number of subjects: 23
Study 2942886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 23
Study 31697801 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab 1.5 mg/kg weekly (group A)
Number of subjects: 85
Study 31697801 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab 3 mg/kg every 2 weeks (group B)
Number of subjects: 85
Study 31697801 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab 6 mg/kg every 4 weeks (group C)
Number of subjects: 85
Study 31697801 — intervention group
Group type: COMPARATOR
Intervention: Emicizumab prophylaxis (intraindividual comparison)
Number of subjects: 85
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: 57FePP+ZnSO4
Number of subjects: 19
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: 57FePP+ZnO
Number of subjects: 19
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: 57FePP-Zn
Number of subjects: 19
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative iron bioavailability from 57FePP+ZnSO4
Number of subjects: 19
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative iron bioavailability from 57FePP-Zn
Number of subjects: 19
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative iron bioavailability from 57FePP+ZnO
Number of subjects: 19
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro solubility from 57FePP+ZnSO4
Number of subjects: 19
Study 28148685 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro solubility from 57FePP+ZnO
Number of subjects: 19
Study 25856686 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg subcutaneously every 12 hours
Number of subjects: 65
Study 25856686 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.5 mg/kg subcutaneously every 24 hours
Number of subjects: 65
Study 23725394 — intervention group
Group type: EXPERIMENTAL
Intervention: Coflex Interlaminar Stabilization
Number of subjects: 150
Study 23725394 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral spinal fusion (PSF)
Number of subjects: 150
Study 23725394 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 22080240 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 73
Study 22080240 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 73
Study 19936044 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 5531
Study 18037713 — intervention group
Group type: EXPERIMENTAL
Intervention: Curd (dahi)
Number of subjects: 80
Study 18037713 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf Protein Concentrate (LPC)
Number of subjects: 80
Study 15521877 — intervention group
Group type: EXPERIMENTAL
Intervention: Epididymal sperm recovery (Group E)
Number of subjects: 151
Study 15521877 — intervention group
Group type: COMPARATOR
Intervention: Testicular sperm recovery (Group T)
Number of subjects: 151
Study 11519776 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/d
Number of subjects: 53
Study 11519776 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg/d
Number of subjects: 53
Study 11519776 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg/d
Number of subjects: 53
Study 11519776 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole
Number of subjects: 53
Study 11519776 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole
Number of subjects: 53
Study 11519776 — intervention group
Group type: COMPARATOR
Intervention: pantoprazole
Number of subjects: 53
Study 11519776 — intervention group
Group type: COMPARATOR
Intervention: omeprazole
Number of subjects: 53
Study 11519776 — intervention group
Group type: COMPARATOR
Intervention: PPIs
Number of subjects: 53
Study 9710365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg for 3 months
Number of subjects: 12
Study 9710365 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 12
Study 7986182 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered sumatriptan succinate
Number of subjects: 0
Study 7986182 — intervention group
Group type: EXPERIMENTAL
Intervention: Second injection of subcutaneously administered sumatriptan succinate
Number of subjects: 0
Study 2645969 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren
Number of subjects: 56
Study 2645969 — intervention group
Group type: COMPARATOR
Intervention: Ketogan
Number of subjects: 56
Study 31900579 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/day for 20 days)
Number of subjects: 11
Study 31900579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29223575 — intervention group
Group type: COMPARATOR
Intervention: TIVA (Propofol and dexmedetomidine)
Number of subjects: 100
Study 28898870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 buccal spray 800 IU/daily
Number of subjects: 24
Study 28898870 — intervention group
Group type: COMPARATOR
Intervention: Oral drops 750 IU/daily
Number of subjects: 24
Study 26347918 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularisation guided by FFR values
Number of subjects: 627
Study 26347918 — intervention group
Group type: COMPARATOR
Intervention: No further invasive treatment after primary PCI of the infarct-related artery only
Number of subjects: 627
Study 23832582 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1995057 intravenous infusion (0.0004, 0.002, and 0.01 mg/kg)
Number of subjects: 28
Study 23832582 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1995057 intravenous infusion
Number of subjects: 28
Study 21827052 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrew with Class III traction
Number of subjects: 20
Study 21827052 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 20
Study 19142662 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased recreational physical activity (3 times/week for 12 weeks)
Number of subjects: 76
Study 19142662 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained same level of physical activity)
Number of subjects: 76
Study 17074624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 40
Study 17074624 — intervention group
Group type: COMPARATOR
Intervention: Single steroid injection
Number of subjects: 40
Study 14872153 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased awareness of hypertension risk and early intervention
Number of subjects: 0
Study 14872153 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic medicine and candidate single nucleotide polymorphisms
Number of subjects: 0
Study 11696141 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl by bolus technique (Group 1, n=8)
Number of subjects: 19
Study 11696141 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl by continuous infusion (Group 2, n=6)
Number of subjects: 19
Study 11696141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam infusion (Group 3, n=5)
Number of subjects: 19
Study 9140018 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 8
Study 9140018 — intervention group
Group type: EXPERIMENTAL
Intervention: S-20098 (5 mg)
Number of subjects: 8
Study 9140018 — intervention group
Group type: EXPERIMENTAL
Intervention: S-20098 (100 mg)
Number of subjects: 8
Study 9140018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8173562 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient individual and family psychotherapy
Number of subjects: 90
Study 8173562 — intervention group
Group type: COMPARATOR
Intervention: Assessment interview only (control group)
Number of subjects: 90
Study 3390962 — intervention group
Group type: EXPERIMENTAL
Intervention: Copal Digital Sphygmomanometer UA251
Number of subjects: 67
Study 31540747 — intervention group
Group type: EXPERIMENTAL
Intervention: High tangent irradiation
Number of subjects: 235
Study 31540747 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment planning designs based on MA.20, EORTC, AMAROS and Z0011 trials
Number of subjects: 235
Study 31540747 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of axillary level II and extension of supraclavicular CTV
Number of subjects: 235
Study 31540747 — intervention group
Group type: COMPARATOR
Intervention: None of the treatment plan designs
Number of subjects: 235
Study 31383427 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin qigong training (exercise group)
Number of subjects: 60
Study 31383427 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group (control group)
Number of subjects: 60
Study 28575729 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg daily (S5 group)
Number of subjects: 25
Study 28575729 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500mg daily (Met group)
Number of subjects: 25
Study 28575729 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle intervention only)
Number of subjects: 25
Study 25816050 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/d)
Number of subjects: 12
Study 25816050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24649781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine (10 ml bolus)
Number of subjects: 32
Study 24649781 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (control group)
Number of subjects: 32
Study 17189218 — intervention group
Group type: EXPERIMENTAL
Intervention: GGCX 8016G>A GG genotype (n = 156)
Number of subjects: 3655
Study 17189218 — intervention group
Group type: EXPERIMENTAL
Intervention: VKORC1 3730G>A and CALU 20943T>A genotypes
Number of subjects: 3655
Study 14649215 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy as an adjunct treatment for cardiovascular disease
Number of subjects: 0
Study 14649215 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved hormone formulations and selective estrogen receptor modulators
Number of subjects: 0
Study 14649215 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of estrogen receptors in vascular tissue
Number of subjects: 0
Study 14649215 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing and dosing for therapeutic intervention
Number of subjects: 0
Study 14649215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanisms of interactions between coagulation proteins, inflammatory cytokines, platelets and the vessel wall
Number of subjects: 0
Study 10397660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluticasone propionate (100 microg per nostril) 4 times daily for 6 days
Number of subjects: 40
Study 10397660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7746690 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (3 doses at 2, 3, and 4 months)
Number of subjects: 108
Study 7746690 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (2 doses with shorter interval)
Number of subjects: 108
Study 1772001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dipyridamole 75 mg t.i.d and acetylsalicylic acid 330 mg t.i.d.
Number of subjects: 2500
Study 1772001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 7042360 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (200 mg t.i.d.)
Number of subjects: 12
Study 7042360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29696990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, affordable technologies to improve mobility and physical activity
Number of subjects: 20
Study 28652278 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day orally, 3 weeks on, 1 week off) + Fulvestrant (500 mg) + Goserelin
Number of subjects: 108
Study 28652278 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Fulvestrant (500 mg) + Goserelin
Number of subjects: 108
Study 28652278 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + Fulvestrant + Goserelin
Number of subjects: 108
Study 26363433 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages
Number of subjects: 230
Study 26363433 — intervention group
Group type: COMPARATOR
Intervention: Paper diaries
Number of subjects: 230
Study 23135760 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF prebiotics (inulin/oligofructose 50/50 mix; 16 g/day for 3 months)
Number of subjects: 30
Study 23135760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study 22112039 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA-free one-step adhesive G-Bond (GC)
Number of subjects: 52
Study 22112039 — intervention group
Group type: COMPARATOR
Intervention: Conventional three-step adhesive Optibond FL (Kerr)
Number of subjects: 52